

May 21, 2021

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai 400001

Subject: Press Release for Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2021

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2021.

Thanking You,

For Dr. Lal PathLabs Limited



Rajat Kalra
Company Secretary and Legal Head



Encl: As above

For Immediate Release

May 21, 2021

Dr. Lal PathLabs Limited records revenue of Rs 431.0 Cr in Q4 FY 2020-21

New Delhi, India, May 21, 2021 – Dr. Lal PathLabs Limited (Dr. Lal PathLabs) today announced that its revenue for the fourth quarter (Q4) of FY 2020-21 was Rs 431.0 Cr, a growth of 42.9% over Q4 FY 2019-20. The revenue for the full year FY 2020-21 was Rs 1,581.3 Cr, a growth of 18.9% over FY 2019-20. The revenue for the first quarter (Q1) of FY 2020-21 was Rs 1,145.0 Cr, a growth of 29.3% over Q1 FY 2019-20. The revenue for the first quarter (Q1) of FY 2020-21 was Rs 1,145.0 Cr, a growth of 29.3% over Q1 FY 2019-20.

Consolidated Performance Highlights: Q4 FY 2020-21 vs Q4 FY 2019-20

Revenue: Rs 431.0 Cr, a growth of 42.9%

Normalised EBITDA at Rs 129.5 Cr with margin at 30.0%

PBT at Rs 110.8 Cr with margin at 25.7%, and

PAT Rs 85.1 Cr with margin at 19.7%

- Revenue for Q4 FY 2020-21 was Rs 431.0 Cr, a growth of 42.9% over Q4 FY 2019-20. The revenue for the full year FY 2020-21 was Rs 1,581.3 Cr, a growth of 18.9% over FY 2019-20. The revenue for the first quarter (Q1) of FY 2020-21 was Rs 1,145.0 Cr, a growth of 29.3% over Q1 FY 2019-20. The revenue for the first quarter (Q1) of FY 2020-21 was Rs 1,145.0 Cr, a growth of 29.3% over Q1 FY 2019-20.
- Normalised EBITDA for Q4 FY 2020-21 was Rs 129.5 Cr, a growth of 101.7% over Q4 FY 2019-20. The normalised EBITDA for the full year FY 2020-21 was Rs 462.6 Cr, a growth of 29.3% over FY 2019-20. The normalised EBITDA for the first quarter (Q1) of FY 2020-21 was Rs 462.6 Cr, a growth of 29.3% over Q1 FY 2019-20. The normalised EBITDA for the first quarter (Q1) of FY 2020-21 was Rs 462.6 Cr, a growth of 29.3% over Q1 FY 2019-20.
- PBT for Q4 FY 2020-21 was Rs 110.8 Cr, a growth of 144.1% over Q4 FY 2019-20. The PBT for the full year FY 2020-21 was Rs 394.4 Cr, a growth of 24.9% over FY 2019-20. The PBT for the first quarter (Q1) of FY 2020-21 was Rs 394.4 Cr, a growth of 24.9% over Q1 FY 2019-20. The PBT for the first quarter (Q1) of FY 2020-21 was Rs 394.4 Cr, a growth of 24.9% over Q1 FY 2019-20.
- PAT for Q4 FY 2020-21 was Rs 85.1 Cr, a growth of 161.0% over Q4 FY 2019-20. The PAT for the full year FY 2020-21 was Rs 296.5 Cr, a growth of 18.8% over FY 2019-20. The PAT for the first quarter (Q1) of FY 2020-21 was Rs 296.5 Cr, a growth of 18.8% over Q1 FY 2019-20. The PAT for the first quarter (Q1) of FY 2020-21 was Rs 296.5 Cr, a growth of 18.8% over Q1 FY 2019-20.
- EPS (Basic) for Q4 FY 2020-21 was Rs 10.10, a growth of 156.3% over Q4 FY 2019-20. The EPS (Basic) for the full year FY 2020-21 was Rs 35.33, a growth of 28.8% over FY 2019-20. The EPS (Basic) for the first quarter (Q1) of FY 2020-21 was Rs 35.33, a growth of 28.8% over Q1 FY 2019-20. The EPS (Basic) for the first quarter (Q1) of FY 2020-21 was Rs 35.33, a growth of 28.8% over Q1 FY 2019-20.
- EPS (Diluted) for Q4 FY 2020-21 was Rs 10.07, a growth of 156.2% over Q4 FY 2019-20. The EPS (Diluted) for the full year FY 2020-21 was Rs 35.25, a growth of 28.8% over FY 2019-20. The EPS (Diluted) for the first quarter (Q1) of FY 2020-21 was Rs 35.25, a growth of 28.8% over Q1 FY 2019-20. The EPS (Diluted) for the first quarter (Q1) of FY 2020-21 was Rs 35.25, a growth of 28.8% over Q1 FY 2019-20.

Dr. Lal PathLabs Limited is a leading provider of diagnostic services in India, offering a wide range of tests and services to its customers. The company is committed to providing high-quality, accurate, and timely diagnostic services to its customers.

Particulars	Q4 FY21	Q4 FY20	Gr %	FY21	FY20	Gr %
Revenue	431.0	301.7	42.9%	1,581.3	1,330.4	18.9%
Expenditure	309.0	244.4		1,145.0	986.8	
EBITDA	122.0	57.3	112.9%	436.3	343.6	27.0%
Adj for Stock Based Compensation & CSR cost	7.5	6.9		26.3	22.0	
Normalised EBITDA	129.5	64.2	101.7%	462.6	365.6	26.5%
Normalised Margins	30.0%	21.3%		29.3%	27.5%	
Other income	13.5	12.0		51.3	55.0	
PBT	110.8	45.4	144.1%	394.4	310.5	27.0%
Margins	25.7%	15.0%		24.9%	23.3%	
PAT	85.1	32.6	161.0%	296.5	227.6	30.3%
Margins	19.7%	10.8%		18.8%	17.1%	
EPS (Basic)	10.10	3.94	156.3%	35.33	27.42	28.8%
EPS (Diluted)	10.07	3.93	156.2%	35.25	27.37	28.8%

□

□A □H □M eI □I. ~ ba□

A □H □M eI □□□ ~ ab□ca d ~ □ a□b ba□eb e b□b □ a□b ~ b□ Fa □Qe de□
~ □ bd ba)~ ~ ab□b)eb□ □ccb□ ~ b □ a□eb e b□ ~ ab □□ a□ db□
ca d ~ □ a□b ba□eb e b□b □ a□b ~ b□c □ b□ b□b ~ d)~ b □a d ~ □ a□eb□
b b ~)~ ~ d□ a□ b b □ca b b□ a□ eb□eb e□ a ~ □

□

□ □ e0.) /-/.□eb□ □e □/0.□ ~ □ ~ b% a dK~ □Obcb b bI □
□Abe □ □Obd □Obcb b bI □H &0)4-2M. b □Pb ~ b@b b %MP@& a6)14M
□M □%RM&F □ b □ ab□ a ~ a □ ~ b)e ~ □ a□ eb□eb e b□ ~ ab □
a□ b□ b □

@ □Ab ~ □

S ba□M e□D b□

@e bc□C ~ □Lcc b□

(6.□/1□0-.32--□

c e + □

(6.□654. .21225□

~ ~□ e ~□

□

C □c eb□c ~ □ □A □H □M eI □bb□ + e + □□

□

□

P cb□E □

Qe □bb b□ ~ □ b b □e □ ~ □c a□ ~ d□ b b □ a d) □□ e □ ~ ~)□ b b □
b ~ d□ □eb□ b b ~ □c bd □ ~ ~ b)□ a□ eb□ b b □b ~ d□ □A □H □M eI □c b□ ~ b □
ab b b □ a□b ~ □bc b□Te b□eb b□c a□ ~ d□ b b □ a b□ □ b b □ a□c b□
b b ~ □ b ~ d□eb□ab b b □c □ ~ b)□□ b□c)□ b ~ ~ b□ a□ eb□ □c □ a□
b□ ab b b □ a□b □a ccb□ b. □c □ □b b ~ □Qeb b□c □ ab) □ b□ □ ~ ba□
)db b □ b)□ b ~)d b b □ a□bd □ b a) b b □□ b □b e db□ a□ b b □
b)□ b ~ b□ b b)□b e d □ab b b)□e db□ □eb□c ~ □ a ~ □c□e a□ ~ b□ab ~ d□ ~ e□
)bd ~ b□ab b b)□ a□ eb□ b□c □e □ a□□ccb □ □ ~ b □ a□c ~ □ bc b□A □H □
M eI □ ab b□ □ ~ d ~ □□ ~ □b ~ b□c a□ ~ d□ b b □□bc b □c b□ b □b b □□
~ b □

□

□

□